Euroapi Company Header Euroapi Company Header

X
[{"orgOrder":0,"company":"PPD","sponsor":"First Wave BioPharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AzurRx BioPharma Engages PPD to Manage Clinical Trial for Niclosamide as Treatment for COVID-19 Gastrointestinal Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"PPD","sponsor":"US Army","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PPD Awarded US Army Study to Help Develop Post-Traumatic Stress Disorder Drugs","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"February 2021","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed"},{"orgOrder":0,"company":"PPD","sponsor":"First Wave BioPharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AzurRx BioPharma Engages PPD to Manage Clinical Trial for Niclosamide as Treatment Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Gastroenterology","graph2":"IND Enabling"},{"orgOrder":0,"company":"PPD","sponsor":"Zogenix","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zogenix Submits Supplemental New Drug Application for FINTEPLA\u00ae (Fenfluramine) for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"PPD","sponsor":"Theratechnologies","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theratechnologies Provides Update on the Dose Escalation Portion of Fast Track Designated TH1902 First-in-Human Study in Advanced Resistant Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"}]

Find Clinical Drug Pipeline Developments & Deals by PPD

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            PPD

            Contact Supplier
            • Development Update

            Details:

            TH1902 (Docetaxel-TH19P01 Conjugate) is Theratechnologies’ proprietary peptide drug conjugate (“PDC”) linked, a well-established and well-characterized cytotoxic agent.

            Lead Product(s): Docetaxel-TH19P01 Conjugate

            Therapeutic Area: Oncology Product Name: TH1902

            Highest Development Status: Phase I Product Type: Peptide

            Recipient: Theratechnologies

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 14, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            PPD

            Contact Supplier
            • Development Update

            Details:

            sNDA is supported by Phase 3 Study 1601 for FINTEPLA® (fenfluramine) for treatment of seizures associated with Lennox-Gastaut Syndrome to FDA. FINTEPLA is approved by the FDA and European Commission for treatment of seizures associated with Dravet syndrome.

            Lead Product(s): Fenfluramine

            Therapeutic Area: Neurology Product Name: Fintepla

            Highest Development Status: Approved Product Type: Small molecule

            Recipient: Zogenix

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 28, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            PPD

            Contact Supplier
            • Deals

            Details:

            PPD will manage the Phase 1b/2a clinical trial using both oral immediate-release tablet and topical rectal enema foam formulations of micronized oral niclosamide, also known as FW-420.

            Lead Product(s): Niclosamide

            Therapeutic Area: Gastroenterology Product Name: FW-420

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: First Wave BioPharma

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration April 13, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            PPD

            Contact Supplier
            • Deals

            Details:

            PPD will work with U.S. Army Medical Materiel Development Activity’s Warfighter Brain Health Project Management Office to test the efficacy and safety of at least two pharmacotherapeutic drugs for the treatment of PTSD in U.S. military active duty personnel and veterans.

            Lead Product(s): Undisclosed

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Undisclosed

            Partner/Sponsor/Collaborator: US Army

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration February 18, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            PPD

            Contact Supplier
            • Deals

            Details:

            Under the terms of the agreement, PPD will manage the Phase 2 clinical trial for an immediate-release capsule formulation of micronized oral niclosamide, also known as FW-1022.

            Lead Product(s): Niclosamide

            Therapeutic Area: Infections and Infectious Diseases Product Name: FW-1022

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: First Wave BioPharma

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement February 09, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY